ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Prolonged Graft Survival in Old Recipients is Abrogated by Immunosuppressive Treatment with CTLA4-Ig

T. Heinbokel,1 M. Quante,1,2 K. Edtinger,1 K. Minami,1 Y. Nian,1 A. Lau,1 A. Elkhal,1 S. Tullius.1

1Transplant Surgery Research Lab, Brigham and Women's Hospital, Boston, MA
2Department of General, Visceral and Transplant Surgery, Tuebingen Unversity Hospital, Tuebingen, Germany.

Meeting: 2018 American Transplant Congress

Abstract number: 162

Keywords: Age factors, Immunosuppression

Session Information

Session Name: Concurrent Session: Novel Therapeutics

Session Type: Concurrent Session

Date: Sunday, June 3, 2018

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:06pm-5:18pm

Location: Room 602/603/604

Although they represent a rapidly growing population, elderly organ transplant recipients are underrepresented in clinical trials. Age-specific aspects of established immunosuppressants are therefore poorly understood.

Here, we assessed the impact of immunosuppressive treatment with CTLA4-Ig, a fusion protein blocking costimulatory signaling between APCs and T cells through CD28, on alloimmune responses in old and young recipients (2-3 months vs. 16 months) in a fully MHC-mismatched murine transplantation models.

While treatment with CTLA4-Ig prolonged skin graft survival in young recipients, the same treatment was unable to prolong graft survival in old recipients. Conversely, cardiac allografts in young mice treated with CTLA4-Ig survived indefinitely, while 80% of old recipients treated with CTLA4-Ig had lost their graft after 100 days (log-rank test, p<0.001; n=5/group).

CTLA4-Ig reduced the in-vivo proliferation of CD4+ and CD8+ T cells (as assessed by BrdU incorporation) uniformly in both young and old recipients; in contrast, CTLA4-Ig reduced CD4+ central-memory and effector-memory T cells only in young but not old recipients. Moreover, systemic frequencies of CD4+IFN-γ+ T cells and systemic levels of IFN-γ cytokine production were reduced in young recipients, but remained unchanged in old. CTLA4-Ig caused significant perturbation in the Treg compartments with reduced frequencies and compromised proliferation of CD4+CD25+Foxp3+ cells. These differences correlated with a significant reduction in expression of CD28 on T cells in old mice, while levels of CTLA4 remained stable.

Immunosuppressive effects of costimulatory blockade with CTLA4-Ig showed distinct age-dependent effects in both skin and cardiac transplantation. Reduced expression of CD28 with aging may represent an escape mechanism for old alloreactive T cells, with unique clinical consequences for immunosuppression in the growing population of elderly transplant recipients.

CITATION INFORMATION: Heinbokel T., Quante M., Edtinger K., Minami K., Nian Y., Lau A., Elkhal A., Tullius S. Prolonged Graft Survival in Old Recipients is Abrogated by Immunosuppressive Treatment with CTLA4-Ig Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Heinbokel T, Quante M, Edtinger K, Minami K, Nian Y, Lau A, Elkhal A, Tullius S. Prolonged Graft Survival in Old Recipients is Abrogated by Immunosuppressive Treatment with CTLA4-Ig [abstract]. https://atcmeetingabstracts.com/abstract/prolonged-graft-survival-in-old-recipients-is-abrogated-by-immunosuppressive-treatment-with-ctla4-ig/. Accessed May 12, 2025.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences